Elixir Medical Corporation的动态

Simultaneous publication in The Lancet of the late-breaking RCT clinical data demonstrating significant benefit of the DynamX? Coronary Bioadaptor System compared to contemporary drug-eluting stent for target lesion failure in complex patient population subsets from the 2400 patients INFINITY-SWEDEHEART RCT. The data included an analysis of patients with acute coronary syndrome (ACS), small vessel lesions, and lesions within the left anterior descending (LAD) artery. #TCT2024